Article Text

PDF
Extended Report
A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial
  1. Mette Bjørndal Axelsen1,2,
  2. Iris Eshed3,
  3. Kim Hørslev-Petersen4,5,
  4. Kristian Stengaard-Pedersen6,
  5. Merete Lund Hetland1,2,7,
  6. Jakob Møller8,
  7. Peter Junker9,
  8. Jan Pødenphant10,11,
  9. Annette Schlemmer12,
  10. Torkell Ellingsen13,
  11. Palle Ahlquist14,
  12. Hanne Lindegaard9,
  13. Asta Linauskas15,
  14. Mette Yde Dam13,
  15. Ib Hansen16,
  16. Hans Christian Horn14,
  17. Christian Gytz Ammitzbøll6,
  18. Anette Jørgensen6,
  19. Sophine B Krintel1,
  20. Johnny Raun4,5,
  21. Niels S Krogh17,
  22. Julia Sidenius Johansen2,18,
  23. Mikkel Østergaard1,2,7,
  24. OPERA study group
  1. Correspondence to Dr Mette Bjørndal Axelsen, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital at Glostrup, Nordre Ringvej 57, opgang 5, stuen, Glostrup DK-2600, Denmark; mbaxelsen{at}gmail.com

Abstract

Objectives To investigate whether a treat-to-target strategy with methotrexate and intra-articular glucocorticosteroid injections suppresses MRI inflammation and halts structural damage progression in patients with early rheumatoid arthritis (ERA), and whether adalimumab provides an additional effect.

Methods In a double-blind, placebo-controlled trial, 85 disease-modifying antirheumatic drug-naïve patients with ERA were randomised to receive methotrexate, intra-articular glucocorticosteroid injections and placebo/adalimumab (43/42). Contrast-enhanced MRI of the right hand was performed at months 0, 6 and 12. Synovitis, osteitis, tenosynovitis, MRI bone erosion and joint space narrowing (JSN) were scored with validated methods. Dynamic contrast-enhanced MRI (DCE-MRI) was carried out in 14 patients.

Results Synovitis, osteitis and tenosynovitis scores decreased highly significantly (p<0.0001) during the 12-months’ follow-up, with mean change scores of −3.7 (median −3.0), −2.2 (−1) and −5.3 (−4.0), respectively. No overall change in MRI bone erosion and JSN scores was seen, with change scores of 0.1 (0) and 0.2 (0). The tenosynovitis score at month 6 was significantly lower in the adalimumab group, 1.3 (0), than in the placebo group, 3.9 (2), Mann–Whitney: p<0.035. Furthermore, the osteitis score decreased significantly during the 12-months’ follow-up in the adalimumab group, but not in the placebo group, Wilcoxon: p=0.001–0.002 and p=0.062–0.146. DCE-MRI parameters correlated closely with conventional MRI inflammatory parameters. Clinical measures decreased highly significantly during follow-up.

Conclusions A treat-to-target strategy with methotrexate and intra-articular glucocorticosteroid in patients with ERA effectively decreased synovitis, osteitis and tenosynovitis and halted structural damage progression as judged by MRI. The findings suggest that addition of adalimumab is associated with further suppression of osteitis and tenosynovitis.

  • Rheumatoid Arthritis
  • Magnetic Resonance Imaging
  • Treatment

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.